SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001824293-23-000166
Filing Date
2023-11-01
Accepted
2023-11-01 08:45:57
Documents
15
Period of Report
2023-11-01
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K val-20231101.htm   iXBRL 8-K 21475
5 GRAPHIC val-20231101_g1.jpg GRAPHIC 16879
6 GRAPHIC val-20231101_g2.jpg GRAPHIC 1656
7 GRAPHIC val-20231101_g3.jpg GRAPHIC 221425
  Complete submission text file 0001824293-23-000166.txt   667221

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20231101.xsd EX-101.SCH 1913
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20231101_lab.xml EX-101.LAB 25850
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20231101_pre.xml EX-101.PRE 13590
9 EXTRACTED XBRL INSTANCE DOCUMENT val-20231101_htm.xml XML 2815
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI BIO, Inc. (Filer) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 231366720
SIC: 2834 Pharmaceutical Preparations